CD274 Expression (Q28444998)

From Wikidata

Jump to navigation Jump to search

genetic variant

EXPRESSION

Language	Label	Description	Also known as
English	CD274 Expression	genetic variant	EXPRESSION

Statements

sequence variant

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

5450525

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

5470547

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

positive therapeutic predictor for

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

3 references

24 February 2021

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

23 May 2022

https://civic.genome.wustl.edu/links/evidence/743

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1167

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

4 references

24 February 2021

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

23 May 2022

https://civic.genome.wustl.edu/links/evidence/743

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1167

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5811

Pembrolizumab for the treatment of non-small-cell lung cancer

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

3 references

24 February 2021

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1167

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1172

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1517

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

Merkel cell carcinoma

statement disputed by

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1578

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

Ipilimumab / nivolumab combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

statement disputed by

Nivolumab plus ipilimumab in advanced melanoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1615

Nivolumab plus ipilimumab in advanced melanoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4857

PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/704

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/704

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

negative therapeutic predictor for

Adaptive radiation therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

head and neck squamous cell carcinoma

1 reference

23 September 2019

https://civic.genome.wustl.edu/links/evidence/3000

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.

positive prognostic predictor for

ovarian serous carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/703

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma

stomach carcinoma

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1275

PD-L1 is an independent prognostic predictor in gastric cancer of Western patients

squamous cell carcinoma of the lung

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/702

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4856

Prognostic value of PD-L1 expression in tumor infiltrating immune cells in cancers: A meta-analysis.

negative prognostic predictor for

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

statement disputed by

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/701

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

non-small-cell lung carcinoma

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/975

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy

papillary thyroid cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1274

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

determination method

CIViC evidence level B

CIViC 2-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4844

Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis

determination method

CIViC evidence level B

CIViC 3-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/4855

Expression of PD-L1 and prognosis in breast cancer: a meta-analysis

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5507

Prognostic significance of PD-L1 in solid tumor: An updated meta-analysis

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

HGVS nomenclature

no value

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/276

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28444998&oldid=2014801407"